A Philadelphia jury has handed up a defense verdict in the latest trial over the adequacy of the warning labels for the blood thinner Xarelto.

The verdict marked the second straight defense verdict out of Philadelphia for drugmakers Bayer and Janssen Pharmaceuticals, which saw similar wins in a string of cases tried last year in federal court. The decision Thursday was rendered after three weeks of trial, and less than a day of jury deliberation.